EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial

Laura S Hansen iD, Lærke S Gasbjerg iD, Andreas Brønden iD, Niels B Dalsgaard iD, Emilie Bahne, Signe Stensen iD, Pernille H Hellmann iD, Jens F Rehfeld iD, Bolette Hartmann iD, Nicolai J Wewer Albrechtsen iD, Jens J Holst iD, Tina Vilsbøll iD und 1 weitere

European Journal of Endocrinology · 2024

DOI: 10.1093/ejendo/lvae095 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Laura S Hansen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Cross-Over Studies, Postprandial Period. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Herlev-Gentofte Hospital's Research Funds, Novo Nordisk Foundation, Novo Nordisk Foundation Center for Basic Metabolic Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Although metformin is widely used for treatment of type 2 diabetes (T2D), its glucose-lowering mechanism remains unclear. Using the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) antagonist exendin(9-39)NH2, we tested the hypothesis that postprandial GLP-1-mediated effects contribute to the glucose-lowering potential of metformin in T2D.

Methods

In a randomized, placebo-controlled, double-blind, crossover study, 15 individuals with T2D (median HbA1c 50 mmol/mol [6.7%], body mass index 30.1 kg/m2, age 71 years) underwent, in randomized order, 14 days of metformin and placebo treatment, respectively. Each treatment period was preceded by 14 days without any glucose-lowering medicine and concluded by two 4 h mixed meal tests performed in randomized order and separated by >24 h with either continuous intravenous exendin(9-39)NH2 or saline infusion.

Results

Compared to placebo, metformin treatment lowered fasting plasma glucose (mean of differences [MD] 1.4 mmol/L × min [95% CI 0.8-2.0]) as well as postprandial plasma glucose excursions during both saline infusion (MD 186 mmol/L × min [95% CI 64-307]) and exendin(9-39)NH2 infusion (MD 268 mmol/L × min [95% CI 108-427]). The metformin-induced improvement in postprandial glucose tolerance was unaffected by GLP-1R antagonization (MD 82 mmol/L × min [95% CI −6564-170]). Metformin treatment increased fasting plasma GLP-1 (MD 1.7 pmol/L × min [95% CI 0.39-2.9]) but did not affect postprandial GLP-1 responses (MD 820 pmol/L × min [95% CI −1750-111]).

Conclusions

Using GLP-1R antagonization, we could not detect GLP-1-mediated postprandial glucose-lowering effect of metformin in individuals with T2D. We show that 2 weeks of metformin treatment increases fasting plasma GLP-1, which may contribute to metformin's beneficial effect on fasting plasma glucose in T2D.

Trial registration

Clinicaltrials.gov NCT03246451

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Cross-Over StudiesPostprandial PeriodGlucagon-Like Peptide 1Blood GlucoseHypoglycemic AgentsHumansMaleFemaleAgedDouble-Blind MethodMiddle AgedPeptide FragmentsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP-1exendin(9-39)NH2metforminrandomized controlled trialtype 2 diabetes

Substanzen

MetforminGlucagon-Like Peptide 1Blood GlucoseHypoglycemic Agentsexendin (9-39)Peptide FragmentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen N, Denmark.
  • Department of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, DK-2400 Copenhagen NV, Denmark.
  • Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, DK-2730 Herlev, Denmark.
  • Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
  • Department of Clinical Biochemistry, Copenhagen University Hospital-Bispebjerg, DK-2400 Copenhagen, Denmark.

ORCID-Profile: Laura S Hansen, Lærke S Gasbjerg, Andreas Brønden, Niels B Dalsgaard, Signe Stensen, Pernille H Hellmann, Jens F Rehfeld, Bolette Hartmann, Nicolai J Wewer Albrechtsen, Jens J Holst, Tina Vilsbøll, Filip K Knop

Förderung

  • Herlev-Gentofte Hospital's Research Funds
  • Novo Nordisk Foundation
  • Novo Nordisk Foundation Center for Basic Metabolic Research
  • University of Copenhagen

Zitieren

APA

Hansen, L. S., Gasbjerg, L. S., Brønden, A., Dalsgaard, N. B., Bahne, E., Stensen, S., Hellmann, P. H., Rehfeld, J. F., Hartmann, B., Wewer Albrechtsen, N. J., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2024). The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae095

Vancouver

Hansen LS, Gasbjerg LS, Brønden A, Dalsgaard NB, Bahne E, Stensen S, et al. The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae095

BibTeX
@article{Hansen2024,
  author = {Hansen, Laura S and Gasbjerg, Lærke S and Brønden, Andreas and Dalsgaard, Niels B and Bahne, Emilie and Stensen, Signe and Hellmann, Pernille H and Rehfeld, Jens F and Hartmann, Bolette and Wewer Albrechtsen, Nicolai J and Holst, Jens J and Vilsbøll, Tina and Knop, Filip K},
  title = {The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial},
  journal = {European Journal of Endocrinology},
  year = {2024},
  doi = {10.1093/ejendo/lvae095}
}
Kostenlos starten →